HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| (54 intermediate revisions by 6 users not shown) | |||
| Line 10: | Line 10: | ||
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | *To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. | *Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. | ||
__TOC__ | |||
<br /> | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable sortable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> | |+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> | ||
|- | |- | ||
| Line 23: | Line 25: | ||
!Prior Notes (4th Edition) | !Prior Notes (4th Edition) | ||
|- | |- | ||
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) | | | ||
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 127: | Line 130: | ||
| | | | ||
|FQR has emailed SR several times, last 4/20/22 | |FQR has emailed SR several times, last 4/20/22 | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING | ||
| Line 203: | Line 222: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING | ||
| Line 254: | Line 289: | ||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | ||
|Disease | |Disease | ||
| | |(Rabail Aslam, MD) | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
| Line 270: | Line 306: | ||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
|9/22/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 286: | Line 322: | ||
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
|9/22/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 302: | Line 338: | ||
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 316: | Line 352: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | !Disease (5th Edition) | ||
|Disease | !Page Type | ||
| | !<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | ||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | |||
|Disease | |||
|Jennelle C. Hodge, PhD | |||
| | | | ||
| | | | ||
|Complete | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 334: | Line 386: | ||
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D. | ||
| | |4/15/25 | ||
| | | | ||
| | | | ||
| Line 350: | Line 402: | ||
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |(Rabail Aslam, MD) | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 366: | Line 419: | ||
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
| | |Gordana Raca MD PhD, | ||
|9/8/25 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 382: | Line 435: | ||
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]] | ||
|Disease | |Disease | ||
|Eric McGinnis, MD | |Eric McGinnis, MD, Fatma Al-Bulushi (trannee) | ||
|12/20/23 | |12/20/23 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 398: | Line 451: | ||
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 405: | Line 458: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 7/16/24. No response as of 9/7/25. | ||
Prior author: Xinjie Xu, PhD, FACMG | |||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Mutated NPM1 | |Acute Myeloid Leukemia (AML) with Mutated NPM1 | ||
|Xinjie Xu, PhD, FACMG | |Xinjie Xu, PhD, FACMG | ||
|Complete | |Complete | ||
| | | | ||
|Add WHO reference | |Add WHO reference<br /> | ||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | ||
|Disease | |Disease | ||
| | |(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D. | ||
| | |4/15/25 | ||
| | | | ||
| | | | ||
| Line 430: | Line 486: | ||
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 437: | Line 493: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 462: | Line 518: | ||
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 469: | Line 525: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: Celeste Eno, PhD | ||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Minimal Differentiation | |Acute Myeloid Leukemia (AML) with Minimal Differentiation | ||
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | |Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | ||
| Line 475: | Line 533: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 494: | Line 568: | ||
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 510: | Line 584: | ||
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | ||
|Disease | |Disease | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|5/1/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 526: | Line 600: | ||
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 533: | Line 607: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myelomonocytic Leukemia | |Acute Myelomonocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 542: | Line 616: | ||
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 549: | Line 623: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Monoblastic and Monocytic Leukemia | |Acute Monoblastic and Monocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 558: | Line 632: | ||
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | ||
|Disease | |Disease | ||
| | |Ashwini Yenamandra PhD FACMG | ||
|5/1/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 574: | Line 648: | ||
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 581: | Line 655: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Megakaryoblastic Leukemia (AMKL) | |Acute Megakaryoblastic Leukemia (AMKL) | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 590: | Line 664: | ||
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | ||
|Disease | |Disease | ||
| | |Yalda Naeini | ||
|6/11/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 625: | Line 699: | ||
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | ||
|Disease | |Disease | ||
| | |(Rabail Aslam, MD) | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 638: | Line 713: | ||
| | | | ||
|Check reference format | |Check reference format | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | ||
|Disease | |Disease | ||
| | |Malini Sathanoori, Ph.D. | ||
|12/6/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 657: | Line 748: | ||
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 664: | Line 755: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: | ||
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |||
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | |MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | ||
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | ||
| Line 756: | Line 848: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]] | |[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]] | ||
|Disease | |Disease | ||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|FQR | |FQR | ||
| Line 772: | Line 864: | ||
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]] | |[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]] | ||
|Disease | |Disease | ||
|Rolando Garcia | |||
|2/7/2025 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|FQR | |FQR | ||
| Line 801: | Line 893: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | ||
| Line 836: | Line 944: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | ||
|Disease | |Disease | ||
| | |(Rabail Aslam, MD) | ||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
|JH_MS | |||
| | | | ||
| | | | ||
| Line 859: | Line 968: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed 5/1/24 | ||
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | |Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | ||
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | |Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | ||
| Line 868: | Line 977: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | ||
|Disease | |Disease | ||
| | |Daynna Wolff, PhD | ||
|5/9/24 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 900: | Line 1,009: | ||
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | ||
|Disease | |Disease | ||
| | |(Rabail Aslam, MD) | ||
Shashi Shetty, Ph.D. | |||
| | |7/1/24 | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 914: | Line 1,024: | ||
|Check reference format | |Check reference format | ||
|- | |- | ||
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) | | | ||
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 962: | Line 1,073: | ||
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | ||
|Disease | |Disease | ||
| | |Daynna Wolff | ||
| | |5/3/2025 | ||
| | |8/3/2025 | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 975: | Line 1,086: | ||
| | | | ||
|Previously within myeloid section under JH/MS editors | |Previously within myeloid section under JH/MS editors | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 989: | Line 1,116: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,005: | Line 1,132: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
| Line 1,026: | Line 1,153: | ||
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]] | |[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,042: | Line 1,169: | ||
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]] | |[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,058: | Line 1,185: | ||
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]] | |[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,074: | Line 1,201: | ||
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]] | |[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,106: | Line 1,233: | ||
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,118: | Line 1,245: | ||
|Complete | |Complete | ||
|10/01/2021 | |10/01/2021 | ||
|Date completed by author: 10/01/2021 | |Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply. | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | | | ||
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 1,152: | Line 1,296: | ||
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | |[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,168: | Line 1,312: | ||
|[[HAEM5:IgG4-related disease|IgG4-related disease]] | |[[HAEM5:IgG4-related disease|IgG4-related disease]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,216: | Line 1,360: | ||
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,227: | Line 1,371: | ||
|Sudha Arumugam, MD | |Sudha Arumugam, MD | ||
|Complete | |Complete | ||
|01/24/2022 | |01/24/2022. Emailed 5/1/2025, no response | ||
|Date completed by author: 01/24/2022 | |Date completed by author: 01/24/2022 | ||
|- | |- | ||
| Line 1,293: | Line 1,437: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | ||
| Line 1,360: | Line 1,520: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | ||
|Disease | |Disease | ||
|Lei Zhang and Michelle Fan (trainee) | |||
|8/8/2024 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|HD | |HD | ||
| Line 1,408: | Line 1,568: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | ||
|Disease | |Disease | ||
|Aiko Otsubo | |||
|6/25/2024 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|HD | |HD | ||
| Line 1,424: | Line 1,584: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | ||
|Disease | |Disease | ||
|Lei Zhang and Michelle Fan (trainee) | |||
|8/8/2024 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|HD | |HD | ||
| Line 1,453: | Line 1,613: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|RESOLVE 4th edition ALL-Related NON-WHO entities content | |RESOLVE 4th edition ALL-Related NON-WHO entities content | ||
| Line 1,474: | Line 1,650: | ||
|- | |- | ||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | ||
| || || || ||Shivani Golem (SG) | | ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG) | ||
| || | | || | ||
|Monoclonal B-cell Lymphocytosis | |Monoclonal B-cell Lymphocytosis | ||
| Line 1,494: | Line 1,670: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem | ||
| || || || ||SG|| || | |7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Hairy Cell Leukemia | |Hairy Cell Leukemia | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| | |Pending WHO 5th e. July 2024 | ||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi | ||
| || || || ||SG|| || | |4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Marginal Zone Lymphoma | |Splenic Marginal Zone Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,511: | Line 1,687: | ||
|- | |- | ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | ||
| || || || ||SG|| || | | || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |Splenic Diffuse Red Pulp Small B-cell Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,527: | Line 1,703: | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior author cannot update the page. | ||
|Hairy Cell Leukemia Variant | |Hairy Cell Leukemia Variant | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,536: | Line 1,712: | ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
|Sent e-mail to prev authors no reply | |||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Email sent to request to update 2024 | ||
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | |(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | ||
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | |(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | ||
| Line 1,552: | Line 1,728: | ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
|Sent e-mail to prev authors no reply | |||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Email sent to request to update 2024 | ||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | ||
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | |Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | ||
| Line 1,570: | Line 1,746: | ||
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | |[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | ||
|Disease | |Disease | ||
|Molly Walkenhorst | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,579: | Line 1,755: | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | |Andrew Ly | ||
| | | | ||
|9/4/2025 sent E-mail reminder | |||
| | | | ||
| | | | ||
| Line 1,602: | Line 1,794: | ||
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,609: | Line 1,801: | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior authors cannot update the page. | ||
|Paediatric Nodal Marginal Zone Lymphoma | |Paediatric Nodal Marginal Zone Lymphoma | ||
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | |* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | ||
|Complete | |Complete; Need new author to update latest content. Primary author cannot update the page. | ||
|11/11/2020 | |11/11/2020 | ||
| | | | ||
| Line 1,620: | Line 1,812: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,636: | Line 1,828: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,650: | Line 1,842: | ||
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | ||
|Disease | |Disease | ||
| | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
| | | | ||
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | |||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior authors cannot update the page. | ||
|Paediatric-Type Follicular Lymphoma | |Paediatric-Type Follicular Lymphoma | ||
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | |*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | ||
|Complete | |Complete; Need new author to update latest content. Primary author cannot update the page. | ||
|8/16/2020 | |8/16/2020 | ||
| | | | ||
| Line 1,668: | Line 1,860: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/ | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,682: | Line 1,874: | ||
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | ||
|Disease | |Disease | ||
| | |Linlin Gao | ||
| | | | ||
|9/4/2025 Sent E-mail to remind | |||
| | | | ||
| | | | ||
| Line 1,698: | Line 1,890: | ||
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,716: | Line 1,908: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |9/4/2025 set E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,730: | Line 1,922: | ||
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]] | |[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]] | ||
|Disease | |Disease | ||
|Farhan Sami | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,739: | Line 1,931: | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|Farhan Sami, MD and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]] | |[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]] | ||
|Disease | |Disease | ||
|Farhan Sami | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,755: | Line 1,963: | ||
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | |Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |Farhan Sami, MD and Shivani Golem, PhD, FACMG | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | ||
| Line 1,775: | Line 1,983: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| || || || ||GC|| || | |5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| || | ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| Line 1,783: | Line 1,991: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|ALK-Positive Large B-cell Lymphoma | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
| | | | ||
| | | | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Large B-cell Lymphoma with IRF4 Rearrangement | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
|Afia Hasnain, MBBS, PhD | |Afia Hasnain, MBBS, PhD | ||
|Complete | |Complete | ||
|5/26/2021 | |5/26/2021. Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Burkitt-Like Lymphoma with 11q Aberration | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
| | |Complete | ||
|27/01/2022 | |27/01/2022 Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
| Line 1,829: | Line 2,037: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | |||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | | || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | ||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | ||
| Line 1,844: | Line 2,068: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Plasmablastic Lymphoma | |Plasmablastic Lymphoma | ||
| Line 1,852: | Line 2,076: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| | | |6/28/2025 | ||
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| || | |||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | ||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| Line 1,867: | Line 2,092: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| | | |5/6/2025 | ||
|8/6/2025 Emailed 9/4/2025 to remind | |||
| || ||GC|| || | |||
|Intravascular Large B-cell Lymphoma | |Intravascular Large B-cell Lymphoma | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | ||
| Line 1,889: | Line 2,116: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |Aiko Otsubo, PhD, Indiana University, Holli Drendel | ||
|Complete | |Complete | ||
|16/11/2021 | |16/11/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | |[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Burkitt Lymphoma | |Burkitt Lymphoma | ||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | ||
|Complete | |Complete | ||
|28/06/2021 | |28/06/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || | |[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || | ||
| Line 1,963: | Line 2,206: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease|| | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu | ||
| | | |5/7/2025 | ||
|8/7/2025 Reminder email sent 9/4/2025|| || | |||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
| Line 1,972: | Line 2,216: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || | |[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD | ||
|7/4/2025 | |||
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,978: | Line 2,224: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] | |[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] | ||
| Line 2,017: | Line 2,279: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease|| | |[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease|| | ||
| || || || ||SG | | || || || ||SG | ||
| || | | || | ||
| Line 2,026: | Line 2,288: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease|| | |[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease|| | ||
| || || || ||SG | | || || || ||SG | ||
| || | | || | ||
| Line 2,043: | Line 2,305: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease|| | |[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease|| | ||
| || || || ||SG | | || || || ||SG | ||
| || | | || | ||
| Line 2,060: | Line 2,322: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease|| | |[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease|| | ||
| || || || | | || || || | ||
|SG | |SG | ||
| Line 2,070: | Line 2,332: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease|| | !Disease (5th Edition) | ||
| || | | !Page Type | ||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | !<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | ||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo and Zhenya Tang | |||
|4/14/25||7/14/25 | |||
9/4/2025 Sent E-mail reminder to Dr. Tang | |||
|Pending|| ||SG | |||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | |||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | |(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | ||
| Line 2,080: | Line 2,360: | ||
|- | |- | ||
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | |[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | ||
| || | | ||9/4/2025 E-mail sent to Dr. Senaratne | ||
| || | |||
|SG | |SG | ||
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | | ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | ||
| Line 2,105: | Line 2,386: | ||
|Prior Notes (4th Edition) | |Prior Notes (4th Edition) | ||
|- | |- | ||
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | | | ||
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 2,184: | Line 2,466: | ||
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | ||
|Disease | |Disease | ||
|Parastou Tizro, MD (trainee); Celeste Eno, PhD | |Parastou Tizro, MD (trainee); Celeste Eno, PhD | ||
|3/17/2024 | |3/17/2024 | ||
| | | | ||
| | |Complete | ||
| | |6/24/2024 | ||
|SK | |SK | ||
| | |7/1/2024 | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,199: | Line 2,480: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS | !Disease (5th Edition) | ||
|3/17/2024 | !Page Type | ||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); Michelle Don, MD, MS | |||
|3/17/2024 (trainee name added on 9/9/24 by JH) | |||
|6/30/24 | |6/30/24 | ||
|Pending | |Pending | ||
| Line 2,239: | Line 2,536: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease|| | |[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | ||
| || | | |7/1/2024||8/31/2024 | ||
|Pending | |||
| ||SK|| || | |||
|Aggressive NK-cell Leukemia | |Aggressive NK-cell Leukemia | ||
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD | |Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ||
| Line 2,247: | Line 2,546: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc | |[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident) | ||
|3/19/2024 | |3/19/2024 | ||
| ||Pending | | ||Pending | ||
| Line 2,278: | Line 2,577: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease|| || | | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | ||
|7/1/2024 | |||
|8/31/224 | |||
|Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,285: | Line 2,588: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease|| | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD | ||
| || | | |7/1/2024||8/31/2024 | ||
|Pending | |||
| ||SK|| || | |||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
|Theresa Spivey, MD, Shashirekha Shetty, PhD | |Theresa Spivey, MD, Shashirekha Shetty, PhD | ||
| Line 2,292: | Line 2,597: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) | ||
| Line 2,304: | Line 2,625: | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD | |[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD | ||
| || | | |6/30/2024 | ||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,376: | Line 2,699: | ||
|3/19/2024 | |3/19/2024 | ||
|6/30/24 | |6/30/24 | ||
| | |Complete | ||
| ||SK|| || | |5/13/24||SK||10/18/24|| | ||
|Hepatosplenic T-cell Lymphoma | |Hepatosplenic T-cell Lymphoma | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
| Line 2,383: | Line 2,706: | ||
|1/21/2021 | |1/21/2021 | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | |[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | ||
Sumire Kitahara, MD | Sumire Kitahara, MD | ||
| || ||Pending | |6/6/24|| ||Pending | ||
| ||SK|| || | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |Anaplastic Large Cell Lymphoma, ALK-Positive | ||
| Line 2,401: | Line 2,740: | ||
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | |[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) | ||
Sumire Kitahara, MD | Sumire Kitahara, MD | ||
| || ||Pending | |6/6/24|| ||Pending | ||
| ||SK|| || | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Negative | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
| Line 2,458: | Line 2,797: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident) | ||
|3/19/2024 | |3/19/2024 | ||
| ||Pending | | ||Pending | ||
| Line 2,474: | Line 2,813: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | |[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | ||
| Line 2,500: | Line 2,855: | ||
| | | | ||
|- | |- | ||
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) | | | ||
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 2,532: | Line 2,888: | ||
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | |[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 2,593: | Line 2,949: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]] | |[[HAEM5:Littoral cell angioma|Littoral cell angioma]] | ||
| Line 2,642: | Line 3,014: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES) | | | ||
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 2,672: | Line 3,045: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| || || || || | | |[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
|N/A||N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,679: | Line 3,058: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| || || || || | |[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,686: | Line 3,072: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || || | |[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||